
Chordate Medical Holding Investor Relations Material
Latest events

Q3 2024
Chordate Medical Holding

Q2 2025
29 Aug, 2025

Q1 2025
23 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Chordate Medical Holding
Access all reports
Chordate Medical Holding AB is a medical technology company that has developed and patented Ozilia Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The company focuses on providing solutions for patients suffering from chronic nasal congestion and chronic migraine, aiming to offer effective and non-pharmacological treatment options. The company is headquartered in Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
CMH
Country
🇸🇪 Sweden